BMY · Bristol Myers Squibb Co
$67.28
+0.27 (+0.40%)
At close · Aug 24
Market Cap
$136.88B
Shares
2.04B
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$48.19B
-0.2%
FY2025
Net Income
$7.05B
+178.8%
FY2025
Gross Margin
72.31%
+3.2pp
FY2020
Diluted EPS
$3.46
+178.5%
FY2025
Operating Cash Flow
$14.16B
-6.8%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 | FY2008 | FY2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $49B – $50B* | $49.19B | $48.19BG | $48.3B | $45.01B | $46.16B | $46.39B | $42.52B | $26.15B | $22.56B | $20.78B | $19.43B | $16.56B | $15.88B | $16.39B | $17.62B | $21.24B | $19.48B | $18.81B | $17.72B | $15.62B | |
| — | $14.68B | $13.94B | $13.97B | $10.69B | $10.14B | $9.94B | $11.77B | $8.08B | $6.47B | $6.01B | $4.97B | $3.91B | $3.93B | $4.62B | $4.61B | $5.6B | $5.28B | $5.14B | $5.32B | $4.92B | |
| — | — | — | — | — | — | — | $30.75B | $18.07B | $16.09B | $14.68B | $14.48B | $12.65B | $11.95B | $11.77B | $13.01B | $15.65B | $14.21B | $13.67B | — | — | |
| — | — | — | — | — | — | — | 72.31% | 69.1% | 71.34% | 70.67% | 74.54% | 76.39% | 75.24% | 71.81% | 73.84% | 73.65% | 72.92% | 72.67% | — | — | |
| — | $10.72B | $9.95B | $11.16B | $9.3B | $9.51B | $10.2B | $10.05B | $6.15B | $6.33B | $6.47B | $5.01B | $5.92B | $4.53B | $3.73B | $3.9B | $3.84B | $3.57B | $3.65B | $3.51B | $3.16B | |
| — | $7.41B | $7.27B | $8.41B | $7.77B | $7.81B | $7.69B | $7.66B | $4.87B | $4.55B | $4.75B | $4.98B | $4.84B | $4.82B | $4.94B | $4.22B | $4.2B | $3.69B | $3.95B | $4.14B | $3.94B | |
| — | $2.72B | $3.5B | $9B | $9.2B | $9.7B | $10.2B | $9.9B | $1.3B | $198M | $190M | $178M | $183M | $286M | $858M | $607M | $353M | $271M | -$170M | — | — | |
| — | — | $4.01B | $9.6B | $9.76B | $10.28B | $10.69B | $10.38B | $1.75B | $637M | $789M | $382M | $376M | $467M | $763M | $681M | $628M | $607M | — | — | — | |
| — | $268M | $563M | $635M | $365M | $75M | $169M | $530M | $301M | $131M | $293M | $109M | $118M | $163M | $226M | $174M | $116M | $113M | $136M | $215M | $180M | |
| — | $37.28B | $38.87B | $56.68B | $36.57B | $38.45B | $38.29B | $49.39B | $21.17B | $16.59B | $15.65B | $13.51B | $14.48B | $13.5B | $13.49B | $15.28B | $14.26B | $13.41B | $13.21B | $12.94B | $13.09B | |
| — | $1.73B | $1.89B | $1.95B | $1.17B | $1.23B | $1.33B | $1.42B | $656M | $183M | $196M | $167M | $184M | $203M | $199M | $182M | $145M | $145M | $184M | $310M | — | |
| — | $514M | $586M | $478M | $449M | $171M | $39M | $121M | $464M | $173M | $126M | $97M | $101M | $101M | $104M | $106M | $91M | $75M | $54M | $130M | — | |
| — | $188M | -$674M | -$893M | $1.16B | -$576M | $720M | $2.31B | -$938M | $854M | $1.69B | $1.45B | $187M | -$210M | -$205M | $80M | $334M | $93M | $381M | -$22M | -$77M | |
| — | $178M | $47M | $44M | -$38M | -$108M | $231M | $72M | -$85M | $93M | $75M | $77M | $83M | $107M | $166M | $183M | $281M | $313M | $550M | $617M | $524M | |
| — | $628M | $280M | $16M | -$160M | -$801M | $745M | $1.23B | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | $11.91B | $9.33B | -$8.38B | $8.44B | $7.71B | $8.1B | -$6.87B | $4.98B | $5.97B | $5.13B | $5.92B | $2.08B | $2.38B | $2.89B | $2.34B | $6.98B | $6.07B | $5.6B | $4.78B | $2.52B | |
| — | $2.63B | $2.27B | $554M | $400M | $1.37B | $1.08B | $2.12B | $1.52B | $1.02B | $4.16B | $1.41B | $446M | $352M | $311M | -$161M | $1.72B | $1.56B | $1.18B | $1.09B | $471M | |
| — | $9.28B | $7.05B | -$8.95B | $8.03B | $6.33B | $6.99B | -$9.02B | $3.44B | $4.92B | $1.01B | $4.46B | $1.57B | $2B | $2.56B | $1.96B | $3.71B | $3.1B | $10.61B | $5.25B | $2.17B | |
| — | — | 14.64% | -18.53% | 17.83% | 13.71% | 15.08% | -21.2% | 13.15% | 21.81% | 4.85% | 22.94% | 9.45% | 12.62% | 15.64% | 11.12% | 17.46% | 15.92% | 56.42% | 29.62% | 13.86% | |
| — | — | — | — | — | $18M | $20M | $20M | $21M | $27M | -$32M | $50M | $66M | $25M | $17M | $541M | $1.55B | $1.41B | $1.25B | $996M | $763M | |
| — | $1.79B | — | — | — | — | — | — | — | — | — | — | — | $2B | $2.56B | $1.96B | $3.7B | $3.09B | $10.55B | — | — | |
| — | $9.54B | $6.77B | -$8.64B | $7.76B | $6.31B | $7.57B | -$9.33B | $4.68B | $4.76B | $1.22B | $4.42B | $1.52B | $1.72B | $3.62B | $1.81B | $3.03B | $3.27B | $10.78B | $3.99B | $2.35B | |
| USD/shares | — | — | $3.47 | -$4.41 | $3.88 | $2.97 | $3.15 | -$3.99 | $2.02 | $3.01 | $0.61 | $2.67 | $0.94 | $1.21 | $1.56 | $1.17 | $2.18 | $1.80 | $5.35 | $2.64 | $1.09 |
| USD/shares | $6.75 – $7.00* | — | $3.46G | -$4.41G | $3.86G | $2.95 | $3.12 | -$3.99 | $2.01 | $3.01 | $0.61 | $2.65 | $0.93 | $1.20 | $1.54 | $1.16 | $2.16 | $1.79 | $5.34 | $2.62 | $1.09 |
| shares | — | — | 2.03B | 2.03B | 2.07B | 2.13B | 2.22B | 2.26B | 1.71B | 1.63B | 1.65B | 1.67B | 1.67B | 1.66B | 1.64B | 1.67B | 1.7B | 1.71B | 1.97B | — | — |
| shares | — | — | 2.04B | 2.03B | 2.08B | 2.15B | 2.25B | 2.26B | 1.71B | 1.64B | 1.65B | 1.68B | 1.68B | 1.67B | 1.66B | 1.69B | 1.72B | 1.73B | 1.98B | — | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2007–FY2025: $35.94B in buybacks, $59.26B in dividends.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
3.48×
Peer median 6.80×
EV/EBIT
—
P/E (TTM)
14.73×
Peer median 39.21×
Peer medians compare against the 8 similar-size Drug Manufacturers - General companies (of 13 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| United States | $33,279,000,000 | $34,105,000,000 | $31,210,000,000 | $31,500,000,000 | $29,214,000,000 | $26,577,000,000 | $15,342,000,000 | $12,586,000,000 |
| Non Us | $13,828,000,000 | $13,199,000,000 | $13,097,000,000 | $13,825,000,000 | — | — | — | — |
| Other Region | $1,087,000,000 | $996,000,000 | $699,000,000 | $834,000,000 | $852,000,000 | $631,000,000 | $524,000,000 | $584,000,000 |
| International | — | — | — | — | $16,319,000,000 | — | — | — |
| Rest of World | — | — | — | — | — | — | $4,013,000,000 | $3,733,000,000 |
| European Union | — | — | — | — | — | $15,310,000,000 | $6,266,000,000 | $5,658,000,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Sales Revenue Gross | $88,085,000,000 | $83,671,000,000 | $73,679,000,000 | $69,633,000,000 | $67,897,000,000 | $60,016,000,000 | — | — |
| Net Product Sales | $46,756,000,000 | $46,778,000,000 | $43,778,000,000 | $44,671,000,000 | $45,055,000,000 | $41,321,000,000 | — | — |
| Growth Brands | $26,409,000,000 | $22,563,000,000 | $19,366,000,000 | $16,757,000,000 | — | — | — | — |
| Legacy Brands | $21,785,000,000 | $25,737,000,000 | $25,640,000,000 | $29,402,000,000 | — | — | — | — |
| Eliquis | $14,443,000,000 | $13,333,000,000 | $12,206,000,000 | $11,789,000,000 | $10,762,000,000 | $9,168,000,000 | $7,929,000,000 | $6,438,000,000 |
| Opdivo | $10,049,000,000 | $9,304,000,000 | $9,009,000,000 | $8,249,000,000 | $7,523,000,000 | $6,992,000,000 | $7,204,000,000 | $6,735,000,000 |
| Orencia | $3,705,000,000 | $3,682,000,000 | $3,601,000,000 | $3,464,000,000 | $3,306,000,000 | $3,157,000,000 | $2,977,000,000 | $2,710,000,000 |
| Revlimid | $2,951,000,000 | $5,773,000,000 | $6,097,000,000 | $9,978,000,000 | $12,821,000,000 | $12,106,000,000 | $1,299,000,000 | $0 |
| Yervoy | $2,900,000,000 | $2,530,000,000 | $2,238,000,000 | $2,131,000,000 | $2,026,000,000 | $1,682,000,000 | $1,489,000,000 | $1,330,000,000 |
| Pomalyst Imnovid | $2,733,000,000 | $3,545,000,000 | $3,441,000,000 | $3,497,000,000 | $3,332,000,000 | $3,070,000,000 | $322,000,000 | $0 |
| Reblozyl | $2,327,000,000 | $1,773,000,000 | $1,008,000,000 | $717,000,000 | $551,000,000 | $274,000,000 | $0 | $0 |
| Other Growth Brands | $1,924,000,000 | $1,643,000,000 | $1,212,000,000 | $1,092,000,000 | — | — | — | — |
| Alliance and Other Revenues | $1,438,000,000 | $1,522,000,000 | $1,228,000,000 | $1,488,000,000 | $1,330,000,000 | $1,197,000,000 | — | — |
| Breyanzi | $1,358,000,000 | $747,000,000 | $364,000,000 | $182,000,000 | $87,000,000 | $0 | $0 | — |
| Opdualag | $1,185,000,000 | $928,000,000 | $627,000,000 | $252,000,000 | $0 | $0 | — | — |
| Camzyos | $1,068,000,000 | $602,000,000 | $231,000,000 | $24,000,000 | $0 | $0 | — | — |
| Other Revenues | $992,000,000 | $1,043,000,000 | $620,000,000 | $746,000,000 | $614,000,000 | $582,000,000 | — | — |
| Other Legacy Brands | $798,000,000 | $925,000,000 | $962,000,000 | $1,162,000,000 | — | — | — | — |
| Zeposia | $577,000,000 | $566,000,000 | $434,000,000 | $250,000,000 | $134,000,000 | $12,000,000 | $0 | $0 |
| Sprycel | $493,000,000 | $1,286,000,000 | $1,930,000,000 | $2,165,000,000 | $2,117,000,000 | $2,140,000,000 | $2,110,000,000 | $2,000,000,000 |
| Alliance Revenues | $447,000,000 | $479,000,000 | $608,000,000 | $742,000,000 | $716,000,000 | $615,000,000 | — | — |
| Abecma | $427,000,000 | $406,000,000 | $472,000,000 | $388,000,000 | $164,000,000 | $0 | $0 | — |
| Abraxane | $368,000,000 | $875,000,000 | $1,004,000,000 | $811,000,000 | $1,181,000,000 | $1,247,000,000 | $166,000,000 | $0 |
| Sotyktu | $291,000,000 | $246,000,000 | $170,000,000 | $8,000,000 | $0 | $0 | — | — |
| Opdivo Ovantig | $238,000,000 | $0 | $0 | — | — | — | — | — |
| Krazati | $205,000,000 | $126,000,000 | $0 | $0 | — | — | — | — |
| Cobenfy | $155,000,000 | $10,000,000 | $0 | $0 | — | — | — | — |
| Augtyro | — | $38,000,000 | $1,000,000 | $0 | $0 | — | — | — |
| Baraclude | — | — | — | — | — | $447,000,000 | — | $744,000,000 |
| Empliciti | — | — | — | $296,000,000 | $334,000,000 | $381,000,000 | $357,000,000 | $247,000,000 |
| In Line Products and New Product Portfolio | — | — | $37,905,000,000 | $35,370,000,000 | $32,383,000,000 | — | — | — |
| In Line Products | — | — | $34,320,000,000 | $33,340,000,000 | $31,300,000,000 | — | — | — |
| Inrebic | — | — | $110,000,000 | $85,000,000 | $74,000,000 | $55,000,000 | $5,000,000 | $0 |
| LOE Products | — | — | $7,101,000,000 | $10,789,000,000 | $14,002,000,000 | — | — | — |
| Mature Products and All Other | — | — | $1,895,000,000 | $2,045,000,000 | $2,234,000,000 | $2,217,000,000 | $2,287,000,000 | $2,357,000,000 |
| New Product Portfolio | — | — | $3,585,000,000 | $2,030,000,000 | $1,083,000,000 | — | — | — |
| Onureg | — | — | $168,000,000 | $124,000,000 | $73,000,000 | $17,000,000 | $0 | $0 |
| Vidaza | — | — | — | — | — | $455,000,000 | — | $0 |
Key facts
CIK
14272
CUSIP
110122108
13F (30d)
1830 filings
1739 filers
Visit website
Investor relations